Telomir Pharmaceuticals, Inc. Common Stock (TELO) Revenue History
Annual and quarterly revenue from 2021 to present
TELO Revenue Over Time (2021–2025)
TELO Revenue Growth History
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | — |
| Q4 2025 | $0 | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $0 | — |
| Q2 2024 | $0 | — |
TELO Revenue Analysis (2021–2025)
Current Revenue & Growth
As of June 22, 2026, Telomir Pharmaceuticals, Inc. Common Stock (TELO) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue
Historical Growth Trajectory
TELO's historical revenue data shows various trends over time.
Peer Comparison
Compared to Healthcare sector peers — including ADTX (-74.1% YoY), AEYE (+11.6% YoY), and INVA (+13.6% YoY). Compare TELO vs ADTX →
TELO Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| TELOCurrent | $0 | - | - | - | |
 ADTX | $3,195 | -74.1% | - | -612542.2% | |
 AEYE | $40M | +11.6% | +14.5% | -7.9% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 LCTX | $15M | +54.6% | +79.9% | -149.6% |
TELO Historical Revenue Data (2021–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $-10,538,849 | - |
| 2024 | $0 | - | $0 | - | $-12,242,174 | - |
| 2023 | $0 | - | $0 | - | $-3,942,048 | - |
| 2022 | $0 | - | $0 | - | $-854,147 | - |
| 2021 | $0 | - | $0 | - | $-138,131 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
5+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
TELO — Frequently Asked Questions
Quick answers to the most common questions about buying TELO stock.
Is TELO's revenue growth accelerating or slowing?
TELO TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is TELO's revenue history from 2021 to 2026?
Telomir Pharmaceuticals, Inc. Common Stock (TELO) revenue history spans 2021 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is TELO's long-term revenue growth rate (CAGR)?
Telomir Pharmaceuticals, Inc. Common Stock's 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for TELO.
Why does TELO's quarterly revenue fluctuate?
TELO quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Telomir Pharmaceuticals, Inc. Common Stock's revenue data from 2021 to 2026 shows full historical quarterly detail on this page.
How is TELO's revenue distributed by segment?
TELO reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does TELO's revenue compare to industry peers?
Telomir Pharmaceuticals, Inc. Common Stock (TELO) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.